<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Asano T</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4> 25-hydroxycholesterol (25HC), produced by cholesterol 25-hydroxylase (CH25H) in macrophages, has been reported to inhibit the replication of viral pathogens such as severe acute respiratory syndrome coronavirus-2. Also, CH25H expression in macrophages is robustly induced by interferons (IFNs). &lt;h4>Objective&lt;/h4> To better understand the serum level increase of 25HC in coronavirus disease 2019 (COVID-19) and how it relates to the clinical picture. &lt;h4>Methods&lt;/h4> We measured the serum levels of 25HC and five other oxysterols in 17 hospitalized COVID-19 patients. &lt;h4>Results&lt;/h4> On admission, 25HC and 27-hydroxycholesterol (27HC) serum levels were elevated; however, 7-ketocholesterol (7KC) levels were lower in patients with COVID-19 than in the healthy controls. There w</pubmed_abstract><journal>Journal of clinical lipidology</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9637049</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Serum 25-hydroxycholesterol levels are increased in patients with coronavirus disease 2019†</pubmed_title><pmcid>PMC9637049</pmcid><pubmed_authors>Matsumura M</pubmed_authors><pubmed_authors>Wakabayashi T</pubmed_authors><pubmed_authors>Okazaki H</pubmed_authors><pubmed_authors>Okada K</pubmed_authors><pubmed_authors>Hatakeyama S</pubmed_authors><pubmed_authors>Sawayama N</pubmed_authors><pubmed_authors>Ebihara K</pubmed_authors><pubmed_authors>Morisawa Y</pubmed_authors><pubmed_authors>Koga Y</pubmed_authors><pubmed_authors>Minami K</pubmed_authors><pubmed_authors>Kondo Y</pubmed_authors><pubmed_authors>Ishibashi S</pubmed_authors><pubmed_authors>Asano T</pubmed_authors><pubmed_authors>Sakurai M</pubmed_authors><pubmed_authors>Oka K</pubmed_authors><pubmed_authors>Takahashi M</pubmed_authors><pubmed_authors>Yamamuro D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Serum 25-hydroxycholesterol levels are increased in patients with coronavirus disease 2019†</name><description>&lt;h4>Background&lt;/h4> 25-hydroxycholesterol (25HC), produced by cholesterol 25-hydroxylase (CH25H) in macrophages, has been reported to inhibit the replication of viral pathogens such as severe acute respiratory syndrome coronavirus-2. Also, CH25H expression in macrophages is robustly induced by interferons (IFNs). &lt;h4>Objective&lt;/h4> To better understand the serum level increase of 25HC in coronavirus disease 2019 (COVID-19) and how it relates to the clinical picture. &lt;h4>Methods&lt;/h4> We measured the serum levels of 25HC and five other oxysterols in 17 hospitalized COVID-19 patients. &lt;h4>Results&lt;/h4> On admission, 25HC and 27-hydroxycholesterol (27HC) serum levels were elevated; however, 7-ketocholesterol (7KC) levels were lower in patients with COVID-19 than in the healthy controls. There w</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-21T23:34:51.11Z</modification><creation>2025-02-19T00:31:17.434Z</creation></dates><accession>S-EPMC9637049</accession><cross_references/></HashMap>